Stephen V Liu: Should patients with stage III ALK NSCLC receive adjuvant alectinib alectinib?

Stephen V Liu shared a post on X:

“POLL: For patients with resected stage III ALK NSCLC who will receive adjuvant alectinib based on ALINA study, should they first receive chemotherapy?”

“Join us in person at DC Lung24 on Saturday, October 19th, to hear Drs. Joshua Reuss and Marina Garassino debate this topic! This one-day IASLC endorsed symposium will cover all the updates in lung cancer with a world-class faculty.

Register now.”

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.